Next-generation incretin peptide therapeutics for type 2 diabetes
Marcadia was a spinout from The University of Indiana that focused on novel diabetes therapeutics. The company's programs were based on novel insights into the incretin pathways (GLP-1, GIP, glucagon) from the lab of Richard DiMarchi, and the company formed multiple partnerships with Merck and Eli Lilly for these assets. Marcadia was acquired in 2010 by Roche.
